Transcript: Q2 2023 AIM ImmunoTech Inc Earnings Call (Aug 16)

https://finance.yahoo.com/news/q2-2023-aim-immunotech-inc-040749819.html

This is the company that owns #Ampligen. There is quite a bit of discussion about the ongoing placebo-controlled trial for #postCOVID condition of fatigue #AMP518

#PwLC #PostCovidSyndrome #MEcfs #CFS #PwME @4183a04c #LongCovid @3a447f2a